Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 22-26.doi: 10.6040/j.issn.1671-7554.0.2017.1036

Previous Articles    

Concerns and perspectives for multigene tests of breast cancer: opportunities and challenges

YU Zhigang, WANG Fei   

  1. Department of Breast Surgery, the Second Hospital of Shandong University;
    Institute of Translational Medicine of Breast Disease Prevention and Treatment, Shandong University, Jinan 250033, Shandong, China)〓山〓东〓大〓学〓学〓报〓(医〓学〓版)56卷1期〓-余之刚, 等.乳腺癌多基因检测的再思考:机遇与挑战〓\=-
  • Published:2022-09-27

PDF (PC)

506

Abstract: Both Oncotype DX® and MammaPrint® have been recommended by American Society of Clinical Onco-logy(ASCO)to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. However, based on current evidence, multigene tests are still regarded supplementary to traditional clinical pathological examinations, and confined to specific patients. Besides, there are still clinical challenges concerning multigene tests: slow concordance of risk assignment by different tests, inaccurate prediction of late recurrences and poor prediction of drug-specific or regimen-specific benefits. In the future, multi-omics characteristic spectrum based on high-throughput technology platforms, innovative prediction models based on interdisciplinary research, and dynamic risk monitoring based on repetitive tests, will offer new opportunities and directions for multigene tests of breast cancer.

Key words: Breast cancer, Multigene test, Oncotype DX®, , MammaPrint®, , Opportunities, Challenges

CLC Number: 

  • R737.9
[1] Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed[M]. New York: Springer International Publishing, 2017.
[2] Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007, 25(33): 5287-5312.
[3] Krop I, Ismaila N, Stearns V. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary[J]. J Oncol Pract, 2017: JOP2017024646. doi: 10.1200/JOP.2017.024646.[Epub ahead of print]
[4] Cossetti RJ, Tyldesley SK, Speers CH, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008[J]. J Clin Oncol, 2015, 33(1): 65-73.
[5] Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy[J]. J Clin Oncol, 2008, 26(2): 246-252.
[6] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
[7] Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006, 24(23): 3726-3734.
[8] van de Vijver MJ, He YD, vant VLJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347(25): 1999-2009.
[9] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci U S A, 2003, 100(14): 8418-8423.
[10] Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13: IL17BR are complementary prognostic factors in early stage breast cancer[J]. Clin Cancer Res, 2008, 14(9): 2601-2608.
[11] Gong G, Kwon MJ, Han J, et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer[J]. Sci Rep, 2017, 7: 45554. doi: 10.1038/srep45554.
[12] Buyse M, Loi S, vant VL, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[13] Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study[J]. Breast Cancer Res Treat, 2009, 116(2): 295-302.
[14] Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-Gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21): 2005-2014.
[15] Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[16] Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20[J]. Breast Cancer Res Treat, 2011, 127(1): 133-142.
[17] 江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.
[18] Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen[J]. Ann Oncol, 2012, 23(11): 2866-2873.
[19] Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8): 1160-1167.
[20] Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer[J]. Lancet, 2005, 365(9460): 671-679.
[21] Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers[J]. J Clin Oncol, 2006, 24(11): 1656-1164.
[22] Iwamoto T, Lee JS, Bianchini G, et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations[J]. Breast Cancer Res Treat, 2011, 130(1): 155-164.
[23] Bianchini G, Iwamoto T, Qi Y, et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer[J]. Cancer Res, 2010, 70(21): 8852-8862.
[24] Györffy B, Hatzis C, Sanft T, et al. Multigene prognostic tests in breast cancer: past, present, future[J]. Breast Cancer Res, 2015, 17: 11. doi: 10.1186/s13058-015-0514-2.
[25] Jahn B, Rochau U, Kurzthaler C, et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant Online[J]. BMC Cancer, 2017, 17(1): 685.
[26] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[27] Abramovitz M, Krie A, Dey N, et al. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy[J]. Curr Opin Oncol, 2016, 28(6): 461-468.
[28] Jinih M, Relihan N, Corrigan MA, et al. Extended adjuvant endocrine therapy in breast cancer: evidence and update — a review[J]. Breast J, 2017, 23(6): 694-705.
[29] Ribnikar D, Sousa B, Cufer T, et al. Extended adjuvant endocrine therapy - a standard to all or some[J]. Breast, 2017, 32: 112-118. doi: 10.1016/j.breast.2017.01.004
[30] Wolmark N, Mamounas EP, Baehner FL, et al. Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression(ESR1)on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14[J]. J Clin Oncol, 2016, 34(20): 2350-2358.
[31] Hequet D, Callens C, Gentien D, et al. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers[J]. PLoS One, 2017, 12(10): e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.
[32] Xu YC, Zhang FC, Li JJ, et al. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients[J]. Oncol Rep, 2015, 34(4): 1883-1894.
[33] He Q, Peng B, Zhuang D, et al. Clinicopathological significance of β-tubulin isotype III gene expression in breast cancer patients[J]. Cancer Biomark, 2015, 15(6): 823-831.
[34] EL Baiomy MA1, El Kashef WF. ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy[J]. Asian Pac J Cancer Prev, 2017, 18(2): 507-513.
[35] He DX, Wu XL, Lu CX, et al. Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer[J]. Oncol Rep, 2017, 38(6): 3392-3402.
[36] Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer[J]. JAMA, 2011, 305(18): 1873-1881.
[37] Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98[J]. J Clin Oncol, 2013, 31(7): 860-867.
[38] 马榕, 王建丽. 乳腺癌多基因检测及其临床意义[J]. 中国实用外科杂志, 2015, 35(7): 701-703. MA Rong, WANG Jianli. Multi-gene testing in breast cancer and clinical significance[J]. Chinese Journal of Practical Surgery, 2015, 35(7): 701-703.
[38] Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents[J]. Cancer Discov, 2012, 2(4): 366-375.
[40] Haynes B, Sarma A, Nangia-Makker P, et al. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management[J]. Cancer Metastasis Rev, 2017, 36(3): 547-555.
[1] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[2] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[3] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[4] LI Tao, YANG Chunlin, DU Tong, LI Heng, WANG Congcong, LI Xiaoli, DUAN Ruisheng,ZHANG Peng. Effects of diabetes mellitus on the subsets and function of NK cells in myasthenia gravis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 31-36.
[5] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[6] LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4+CD25+FoxP3+ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 50-54.
[7] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[8] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[9] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[10] KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78.
[11] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
[12] YOU Xueting, TIAN Xingsong. Analysis of clinicopathological characteristics of 3 514 cases of breast cancer over 9 years [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 49-54.
[13] CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017 [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16.
[14] LIU Yinhua, ZHAO Jingyi, XIN Ling. Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 1-5.
[15] SHI Aiping, XU Gege, XIE Xinpeng. Review of neoadjuvant therapy for breast cancer at the St.Gallen conference [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 6-11.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd